Schröck Andreas, Göke Friederike, Wagner Patrick, Bode Maike, Franzen Alina, Huss Sebastian, Agaimy Abbas, Ihrler Stephan, Kirsten Robert, Kristiansen Glen, Bootz Friedrich, Lengerke Claudia, Perner Sven
Department of Otorhinolaryngology / Head and Neck Surgery, University of Bonn, Germany; Department of Prostate Cancer Research, University of Bonn, Bonn, Germany.
Head Neck. 2014 Sep;36(9):1253-7. doi: 10.1002/hed.23443. Epub 2014 Feb 1.
Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer.
One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker.
FGFR1 amplification was found in subsets of sinonasal SCCs (20%), carcinomas associated with an inverted papilloma (33%), and SNUCs (5%). In all cases, metastatic tumor samples shared the same FGFR1 amplification status as the corresponding primary tumor tissue. None of the FGFR1-amplified tumors expressed p16.
FGFR1 amplification represents a potential molecular target in a subset of patients with sinonasal cancer. © 2014 Wiley Periodicals, Inc. Head Neck 36: 1253-1257, 2014.
尽管采用了多模式治疗，但鼻窦恶性肿瘤的预后仍不理想。本研究的目的是阐明这些肿瘤是否存在成纤维细胞生长因子受体1（FGFR1）基因扩增，该基因最近已被确定为鳞状细胞肺癌的潜在治疗靶点。
通过荧光原位杂交（FISH）评估112例原发性肿瘤（包括鳞状细胞癌[SCC]、伴内翻性乳头状瘤的癌、鼻窦未分化癌[SNUC]、腺癌、腺样囊性癌[ACC]、嗅神经母细胞瘤以及9例相应的淋巴结转移灶）的FGFR1拷贝数状态。通过p16免疫组化评估人乳头瘤病毒（HPV）状态作为替代标志物。
在部分鼻窦SCC（20%）、伴内翻性乳头状瘤的癌（33%）和SNUC（5%）中发现FGFR1扩增。在所有病例中，转移瘤样本与相应的原发肿瘤组织具有相同的FGFR1扩增状态。所有FGFR1扩增的肿瘤均未表达p16。
FGFR1扩增代表了一部分鼻窦癌患者的潜在分子靶点。©2014威利期刊公司。《头颈》2014年第36卷：1253 - 1257页。
